ORGANIC
LETTERS
2008
Vol. 10, No. 17
3737-3739
Total Synthesis of a Marine Alkaloid
from the Tunicate Dendrodoa
grossularia
Christopher D. Hupp and Jetze J. Tepe*
Department of Chemistry, Michigan State UniVersity, East Lansing, Michigan 48824
Received June 18, 2008
ABSTRACT
A short synthesis of an indole marine alkaloid (1) from the tunicate Dendrodoa grossularia is described. The key step in the synthesis
involves a novel twist on an underutilized oxazole rearrangement, which produces the quaternary stereocenter in the molecule.
Marine organisms have been a large source of synthetically
interesting and pharmacologically important natural prod-
ucts.1-4 Furthermore, the synthetic challenge of many natural
products often attracts the curious organic chemist. Even
some of the smaller marine natural products hold some
intriguing structural scaffolds as well as hidden utility.5
The tunicate Dendrodoa grossularia, a red marine organ-
ism that grows along the coasts of Brittany and in the Baltic
and North Seas, contains small heterocyclic alkaloids with
unique scaffolds.6-11 Biological studies on indole alkaloids
from this tunicate displayed moderate cytotoxicity toward
the L1210 leukemia cell line (4-10 µg/mL) and up to 10
ng/mL for the MCF7 and WiDr cell lines.11,12 The latest
compound (1) to come from this tunicate was isolated in
1998 and to the best of our knowledge has not been
synthesized to date.13
As a continuation of our laboratory’s focus on the
development of new heterocyclic methodologies for the
syntheses of pharmacologically significant scaffolds,14 we
report the racemic total synthesis of indole alkaloid 1.15
The key step in forming the quaternary stereocenter in the
alkaloid utilizes a novel oxazole rearrangement16,17 producing
an oxazolone intermediate, ultimately leading to a quaternary
hydantoin.
(1) Barsby, T. Trends Biotechnol. 2006, 24, 1–3
(2) Gul, W.; Hamann, M. T. Life Sci. 2005, 78, 442–453
(3) Jha, R. K.; Zi-rong, X. Mar. Drugs 2004, 2, 123–146
(4) Simmons, T. L.; Andrianasolo, E.; McPhail, K.; Flatt, P.; Gerwick,
W. H. Mol. Cancer Ther. 2005, 4, 333–342
(5) Baker, D. D.; Alvi, K. A. Curr. Opin. Biotechnol. 2004, 15, 576–
583.
(6) Guyot, M.; Meyer, M. Tetrahedron Lett. 1986, 27, 2621–2
(7) Heitz, S.; Durgeat, M.; Guyot, M.; Brassy, C.; Bachet, B. Tetrahedron
Lett. 1980, 21, 1457–8
(8) Moquin, C.; Guyot, M. Tetrahedron Lett. 1984, 25, 5047–8
(9) Loukaci, A.; Guyot, M. Magn. Reson. Chem. 1996, 34, 143–5
.
(12) Helbecque, N.; Moquin, C.; Bernier, J. L.; Morel, E.; Guyot, M.;
.
Henichart, J. P. Cancer Biochem. Biophys. 1987, 9, 271–9.
.
(13) Loukaci, A.; Guyot, M.; Chiaroni, A.; Riche, C. J. Nat. Prod. 1998,
61, 519–522.
.
(14) Fisk, J. S.; Mosey, R. A.; Tepe, J. J. Chem. Soc. ReV. 2007, 36,
1432–1440.
(15) The natural product (1) was derivatized and crystallized out as a
racemic mixture as described in ref 13.
.
(16) Engel, N.; Kubel, B.; Steglich, W. Angew. Chem., Int. Ed. 1977,
.
16, 394–396.
.
(17) Kubel, B.; Hofle, G.; Steglich, W. Angew. Chem., Int. Ed. 1975,
.
14, 58–59
.
(10) Bergmann, T.; Schories, D.; Steffan, B. Tetrahedron 1997, 53,
(18) (a) Kharasch, M. S.; Kane, S. S.; Brown, H. C. J. Am. Chem. Soc.
1940, 62, 2242–3. (b) Garg, N. K.; Sarpong, R.; Stoltz, B. M. J. Am. Chem.
2055–2060
.
(11) Moquin-Pattey, C.; Guyot, M. Tetrahedron 1989, 45, 3445–50
.
Soc. 2002, 124, 13179–13184.
10.1021/ol801375k CCC: $40.75
Published on Web 08/05/2008
2008 American Chemical Society